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Scott Ouillette, Southern Maine Community College. Instructor: Lisa Dietrich, Southern Maine Community College/Maine Medical Center
Abstract
As cardiovascular disease continues to be the number one killer of 
humans across the globe, a new approach in treatment and prevention 
needs to be found. Angiogenesis is a promising young field of study that 
can change the way we treat patients with cardiovascular 
complications.
        
Introduction
Cardiovascular Disease: 17.3 million deaths worldwide each year
Current Treatments: Medication, CABG surgery, Minimally invasive 
coronary reperfusion.
Angiogenesis: Is the natural process that our bodies use to create new 
blood vessels from preexisting ones. Angiogenesis usually occurs in the 
development process of life but can occur afterward as a response to 
blood vessel damage. It is also used by tumors to recruit new blood 
vessels to feed cancer cells with oxygen and nutrients, which allow them 
to grow. In relation to heart disease, angiogenesis is the body's 
response to blocked arteries by creating new blood vessels (called 
collaterals) to bypass the blockage and restore blood flow downstream 
to the affected artery. In order for angiogenesis to occur, biological 
signals known as angiogenic growth factors are sent to the receptors on 
the endothelial layers of the blood vessel that is requesting new blood 
flow. Once the basement membrane of the blood vessel has degraded 
enough, the new vessel escapes the old vessel and starts to grow 
towards the source of the original growth factor signal. [Figures 1,2]
Accelerating or enhancing the body's natural response to blood vessel 
injury and tissue damage is not a new concept. In the early 2000’s 
scientists pioneered therapeutic angiogenesis by showing the effects 
Vascular endothelial growth factor had in re-perfusing blood flow in a 
rabbit hindlimb after blood flow was cut off, this research proved that a 
single growth factor could have positive effects to promote 
angiogenesis in patients suffering from heart disease. 
Current Research Focuses on three approaches: Gene therapy’s overall 
goal is to make the body's cells increase angiogenic production when 
they are triggered by re-writing the host's genetic makeup. Cell therapy 
involves the use of several stem and progenitor cells like bone marrow 
to build new vessels through stimulation of growth factors that are 
triggered by local paracrine release after ischemia. Protein therapy 
involves the introduction of growth factors themselves directly into the 
patient. This is achieved by local or general administration (pumps, IV, 
scaffolds, injection). In both forms of delivery, the protein is released for 
a certain amount of time and in certain doses. Though protein therapy is 
very effective, the argument against, is that proteins rapidly diffuse in 
vivo. So bolus injection doesn't work. Controlled release shows the most 
promise but is also the most challenging. The ideal agent should be 
potent, be able to target ishemic tissue, have sustained release, no side 
effects, adequate exposure, and should not need readministration.
Hypothesis
Up until this point research has only focused on angiogenic activators and 
ineffective growth factor administration 
Focusing on the angiogenic switch and the use of a bioresorbable stent coated 
with angiogenic growth factors and anti-inhibitors for prolonged local 
administration would solve the problems with dosage and controlled release that 
could push therapeutic angiogenesis over the edge as an extremely effective 
treatment for cardiovascular disease
Methods
The way angiogenesis is triggered in the body has many different steps and can be 
broken down into 3 categories: The mechanical trigger, the chemical trigger, and 
the molecular trigger. The process as a whole is more commonly known as the 
angiogenesis signaling cascade.
Because mechanical triggers are not well known and chemical triggers is the 
body's natural response to blockages during tissue hypoxia, the molecular trigger 
makes more sense for growth factor therapy. The centerpiece of angiogenesis 
research revolves around the growth factors that activate or inhibit blood vessel 
growth. To this date there are 19 known angiogenic growth factors and over 300 
angiogenesis inhibitors. Fibroblast growth factor (FGF) is one of the most 
researched growth factor families, it is also one of the most effective. Another 
important stimulant is vascular endothelial growth factor (VEGF), which causes a 
large signaling cascade in endothelial cells to create new capillaries. On the other 
hand, angiogenic inhibitors are far more well known in large part to the research 
done using them as anti-cancer treatments in the 1970s. As a result of their 
obvious mechanism, the inhibitors are often overlooked in therapy. But inhibitors 
play a key role in the activation of blood vessel development. Because 
angiogenesis is such a tightly controlled balance of counteracting factors, checking 
the inhibitors and promoting the activators flicks a “switch” that allows new blood 
vessels to begin growing. This is better known as the balance hypothesis for the 
angiogenic switch. [Figure 3]
Next Steps
•Development of a stent based delivery system focusing on protein therapy/ 
growth factor release and disabling growth factor inhibitors
•Continued research into finding the most effective growth factors
•Animal and human clinical trials using these new methods
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Figure 2. Angiogenesis naturally bypassing a coronary artery blockage using multiple current delivery methods 
of growth factors. Each method has varying degrees of success in unique situations.
Figure 3. Visualization of the angiogenic switch. Important growth factors and inhibitors shown. For 
therapeutic angiogenesis to be successful the correct activators and suppression of inhibitors must be utilized.
Figure 1. Schematic showing the various stages of angiogenesis. Ischemia/hypoxia, growth factor release, 
endothelial degradation (A). Proliferation of endothelial cells, cell recruitment (B). Cell migration through the 
extracellular matrix (C). Tube formation, lumen formation, vessel remodeling (D).
